Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: European J Org Chem. 2013 Jan 3;3013(6):1107–1115. doi: 10.1002/ejoc.201201190

A New Route to Azafluoranthene Natural Products via Direct Arylation

Shashikanth Ponnala a, Wayne W Harding a,*
PMCID: PMC3597128  NIHMSID: NIHMS442499  PMID: 23503080

Abstract

Microwave-assisted direct arylation was successfully employed in the synthesis of azafluoranthene alkaloids for the first time. Direct arylation reactions on a diverse set of phenyltetrahydroisoquinolines produces the indeno[1,2,3-ij]isoquinoline nucleus en route to a high yielding azafluoranthene synthesis.

The method was used as a key step in the efficient preparation of the natural products rufescine and triclisine. As demonstrated herein, this synthetic approach should be generally applicable to the preparation of natural and un-natural azafluoranthene alkaloids as well as “azafluoranthene-like” isoquinoline alkaloids.

Keywords: Alkaloid, C-H Activation, Total Synthesis

Introduction

Azafluoranthene alkaloids have been identified as secondary metabolites in Abuta,[1] Triclisia,[2] Telitoxicum,[3] Stephania,[4] Cissampelos[5] and Pericampylus[6] species of the Menispermaceae family. Typical members include rufescine (1), imeluteine (2) and triclisine (3). This class of alkaloids shares some structural similarities to aporphine alkaloids such as nantenine (4).[7] Naturally occurring members of both alkaloid classes have oxygenated functionalities (typically hydroxy, methoxy or methylenedioxy groups) decorating the biphenyl sub-structure.

Aporphine and azafluoranthene alkaloids have displayed interesting biological activities. Aporphine alkaloids have been shown to possess anticancer activity and there is evidence that this activity is exerted via induction of apoptosis, inhibiting cell proliferation and inhibiting DNA topoisomerase.[8] Some members display acute hypotensive effects[9] and anticonvulsant and antinociceptive activities have also been reported.[10] In the realm of central nervous system (CNS) activity, aporphines have been studied as ligands for dopaminergic (D1 and D2), adrenergic and serotonergic receptors.[11] The dopamine D1/D2 receptor agonist apomorphine is currently used as a treatment for Parkinson's Disease.[10d] A number of aporphines are also known to be inhibitors of acetylcholinesterase, an enyzme that is the biological target of clinically available Alzheimer's Disease therapeutics.[12] Our own work on aporphines have explored the synthesis and bioactivity of nantenine derivatives as serotonin 5-HT2A and α1A adrenergic receptor antagonists,[13] cytotoxic agents[14] and acetylcholinesterase inhibitors.[15]

As compared to aporphines, much fewer azafluoranthene natural products are known. Nevertheless, members of the azafluoranthene class of natural products have shown promising biological activity as anti-HIV[6], antifungal and cytotoxic[5, 16] agents. Recently, the cytotoxic activity of the azafluoranthene eupolauridine was attributed to targeting of DNA topoisomerase II[17] In addition to the biological activities mentioned, the extensive conjugation in molecules containing the azafluoranthene core endow them with interesting spectral properties. For this reason, they have been studied as potentially useful agents in luminescent and electroluminescent applications and devices.[18]

A number of strategies have been investigated for the synthesis of azafluoranthenes. The construction of the aryl-aryl bond is usually a key step in reported methods. Pschorr-based cyclization,[1a, 19] photocylization[20] and oxidative biaryl cylization of isoquinoline precursors with toxic vanadium-based reagents[21] have been successfully implemented in this regard. These methods suffer from low to moderate yields for the biaryl coupling step. Other strategies include: remote metalation cross-coupling on biaryl precursors,[22] inverse electron demand Diels-Alder reaction of 3-carbomethoxy-2-pyrones[23], intramolecular aza-Wittig condensation on fluorenone derivatives[24] and microwave-assisted electrocyclization of aza-ene intermediates.[25] These latter routes have the drawback of low-yielding steps or require long synthetic sequences. Synthetic approaches that are improved in efficiency and overall yield are desirable at this time, especially within the context of accessing diverse libraries of azafluoranthene analogs in order to fully exploit their bioactive potential.

We have recently deployed microwave-assisted direct arylation methods to prepare aporphine[13c, 13e] and C-homoaporphine alkaloids.[26] By analogy, we expected a similar strategy to be applicable to the synthesis of azafluoranthene alkaloids. It was envisaged that this method could offer improved alternatives to other reported methods in terms of efficiency and yields.

Results and Discussion

The key step in our anticipated synthesis of azafluoranthenes (5, Figure 2), required the preparation of a phenyltetrahydroisoquinoline intermediate (6). Such compounds are readily prepared via a Pictet-Spengler reaction with protected amine 7 and bromoaldehyde 8. This strategy is analogous to the method pioneered by the Fagnou group for the synthesis of aporphine alkaloids in which intramolecular direct arylation was used to construct the biaryl bond of the aporphine core.[27] In these prior works, the facility of various phosphine ligands for the direct arylation process under thermal conditions was demonstrated. The reaction was shown to be tolerant of a wide variety of substitution patterns (including electron-withdrawing groups) in both aromatic rings. We recently applied a variation of this method in which microwave irradiation was used (instead of thermal conditions) for the biaryl coupling step in the synthesis of aporphines.[13c]

Figure 2.

Figure 2

Retrosynthetic analysis for azafluoranthene synthesis

Efforts initially focused on optimization of the biaryl cyclization of the tetrahydroisoquinoline substrate 11. Our interest in this regard stemmed from a desire to prepare analogs of the aporphine alkaloid nantenine (4), as part of our ongoing structure-activity relationship (SAR) studies on nantenine-like molecules at central nervous system (CNS) receptors.[13a, 13b, 13e] Compound 11 was prepared from readily available[28] 9, and commercially available 10 as shown in Scheme 1.

Scheme 1.

Scheme 1

Synthesis of biaryl coupling substrate 11

With 11 in hand, we proceeded to evaluate the optimal combination of ligand, base and solvent required for microwave-assisted direct biaryl cyclization.

Table 1 summarizes the results of this study. Based on the demonstrated utility of Buchwald phosphine ligands such as PhDavePhos (ligand A) and DavePhos (ligand B) as well as di-tert-butyl(methyl)phosphine tetrafluoroborate (ligand C) for direct arylations to prepare similar (aporphine and homoaporphine) scaffolds,[13c, 2627, 29] we decided to investigate these ligands.

Table 1.

Optimization of direct arylation on 11

graphic file with name nihms442499t1.jpg
Entry Ligand Base Solvent Yield (%)a
1 A K2CO3 DMA 0
2 B K2CO3 DMA 26
3 C K2CO3 DMA 31
4 A Cs2CO3 DMSO 0
5 B Cs2CO3 DMSO 0
6 C Cs2CO3 DMSO 38
7 A K2CO3 DMSO 12
8 B K2CO3 DMSO 41
9b C K2CO3 DMSO 91
a.

Isolated yields. Reactions run on a 0.1 mmol scale.

b.

Under thermal conditions, the yield of this combination was 82% after 24h.

Ligand A, was ineffective in achieving high-yielding cyclization irrespective of the solvent or base tried (entries 1, 4 and 7). In the case of ligand, the best yield (41%, entry 8) was obtained using K2CO3 as base and DMSO as solvent. Cs2CO3 performed poorer than K2CO3 when either ligand A or B was used with DMSO as solvent (entries 4 and 5). Generally, the combination of K2CO3/DMSO gave higher yields than other base/solvent combinations used with a particular ligand (eg. compare entries 2 and 8; entries 3 and 9). Yields tended to be higher with ligand C as compared to the other ligands (entries 3, 6 and 9). The highest yield (91%) was obtained with a ligand C/K2CO3/DMSO combination.

Having optimized the direct arylation on 11, we next turned our attention to examining the scope of the reaction with other substrates (13a – 13n, Table 2). These substrates were prepared in a manner similar to that depicted in Scheme 1 (yields ranged from 70% – 95%). As shown in Table 2, high yields were obtained consistently with a variety of aryl ring substitution patterns, highlighting the utility of the method in producing the indeno[1,2,3-ij]isoquinoline core as a precursor to azafluoranthene natural products.

Table 2.

Direct arylation with other substrates

graphic file with name nihms442499t2.jpg
Cmpd R1 R2 R3 R4 R5 R6 Yield
(%)
14a Me Me H H OMe OMe 89
14b Me Me H H F H 86
14c Me Me H H OH H 81
14d Me Me H H OMe H 83
14e Me Me H H H H 82
14f Me H H H F H 77
14g Me H H H OMe H 82
14h Me H H H H H 81
14i H Me H H F H 76
14j H Me H H O OCH2 81
14k H Me H H OMe H 77
14l H Me H H OMe OMe 79
14m Me Me OMe OMe OMe H 93
14n Me Me OMe H OMe H 91

In continued explorations of the direct arylation reaction, coupling of substrate 15 (in which the aryl bromide partner is the incipient ring A of the azafluoranthene nucleus) was attempted. The impetus for inverting the arylation partners in this way was based on the ready availability of several benzaldehydes and heteroaromatic aldehydes (as inputs for the Pictet-Spengler reaction) for later library diversification. We found that this direct arylation proceeded to give 14d but in poor yield (Scheme 2). This result was unexpected in light of current understanding of the mechanism of direct arylation.

Scheme 2.

Scheme 2

Alternative coupling approach

Fagnou and others have provided evidence for a concerted metalation-deprotonation (CMD) pathway in direct arylation reactions with simple or electron deficient aromatics.[30] In this context, electron-deficient aromatic rings (as the non-halide containing coupling partner) react more easily than electron-rich ones.[30b] The acidity of the C-H bond in the unactivated ring is important; the more acidic this proton the more facile is deprotonation and the CMD pathway overall. On the basis of these considerations, we would expect that inversion of the coupling partners as in Scheme 2 should result in more facile coupling. Since this was not the case, it appears that inversion of partners in this intramolecular framework alters the mechanistic pathway in some way. In the absence of detailed mechanistic studies, we postulate that metalation of substrate 15 is less favorable for steric reasons (the halide is ortho to two substituents) and this combined with reduced C-H acidity in the arene ring, negatively impacts the CMD process. No attempts were made to optimize this reaction.

We then turned our attention to the transformation of the cyclized products 12 and 14 to azafluoranthenes. For this task, we focused on synthesis of 17 (Scheme 3) as well as the natural products rufescine (1) and triclisine (3). Our initial plan was to deprotect the N-ethyl carbamate group and then oxidize the resulting tetrahydroisoquinoline moiety to an isoquinoline.

Scheme 3.

Scheme 3

Synthesis of nantenine analog 17, rufescine (1) and triclisine (3)

However, when deprotection of the substrates 14n and 14e was attempted with aqueous NaOH/DMSO, this gave the hydroxylated products 16a and 16b respectively. After some experimentation, we found that deprotection of the carbamate and oxidation to the isoquinoline moiety could be effected in a single pot by heating the compounds with DBU in an atmosphere of dry oxygen.[31] Mechanistically, this latter reaction involves removal of a benzylic proton, elimination of the carbamate group and oxidation of the dihydroisoquinoline thus formed. We are uncertain of the mechanism of the benzylic hydroxylation in the formation of 16a and 16b at present; our observations are however consistent with a requirement for oxygen and water for benzylic hydroxylation. A similar benzylic hydroxylation in the synthesis of 5,6,8,12b-tetrahydroisoindoldo[1,2-A]isoquinolin-8-ones has been reported.[32] Here, formation of a benzylic carbanion under the strongly basic conditions used (0.5M KOH/MeOH, air, reflux) is thought to precede the formation of a doubly benzylic radical species via reaction of the carbanion with molecular oxygen.[32] It is possible that this mechanism is in operation in the case at hand. Interestingly, when 16a or 16b was heated with DBU/DMSO no reaction occurred, highlighting the fact that 16a and 16b are not formed as intermediates in the oxidation of 14n and 14e with DBU/DMSO to 1 and 3 respectively.

To further examine the utility of this method in constructing novel “azafluoranthene-like” isoquinoline-containing heterocycles, we decided to prepare compound 21. Thus, compounds 18a and 18b were prepared using standard methods (see Experimental Section) and subjected to the optimized microwave-assisted arylation conditions (Scheme 4). Although inversion of the arylation partners did not give a high yield of biaryl coupled product in the synthesis of 14d (Scheme 2), in the case of 18a, compound 19 was obtained in 91% yield. (In this case, the increased C-H acidity of the pyridyl moiety as compared to the C-H acidity of the anisole moiety of 15, probably compensates for the increased steric demand in metalation). As observed, the biaryl cyclization was accompanied by benzylic hydroxylation. Although moisture and air were rigorously excluded from this reaction in several attempts, we never isolated the un-hydroxylated cyclized product. Presumably, the pyridine moiety increases the propensity for benzylic oxidation of the initially formed cyclized product. This oxidation seems to occur very rapidly, probably during the work-up procedure. (We also observed similar benzylic hydroxylation of 14a - 14n but this was considerably slower; samples of 14a - 14n were 20 – 50% hydroxylated as estimated by TLC, after exposure to air for 24 hours). Attempts to achieve biaryl cyclization with substrate 18b using our typical conditions were unsuccessful; the starting material was consumed but cyclized product could not be identified from the complex mixture produced.

Scheme 4.

Scheme 4

Synthesis of "azafluoranthene-like" alkaloid 21

Compound 19 was transformed to the dihydroisoquinoline 20 by treatment with TFA. The novel isoquinoline 21 was prepared by oxidation of 20 in the presence of DBU.

Conclusions

Microwave-assisted direct arylation is a powerful method for assembly of the indeno[1,2,3-ij]isoquinoline nucleus en route to azafluoranthene alkaloids. The arylation reaction under microwave conditions is rapid and is tolerant of a wide variety of substitution patterns in the aryl rings. Azafluoranthenes are easily accessed in 3 high-yielding steps (Pictet-Spengler reaction, microwave-assisted direct arylation and deprotection/oxidation) from readily available starting materials. This straightforward route offers considerable advantages over existing ones in terms of overall yields, efficiency and accessibility to compound diversity. Further work is continuing on the applicability of the method to other novel “azafluoranthene-like” isoquinoline scaffolds and assessment of the cytotoxicity and CNS receptor activity of these molecules. Our findings will be reported in due course.

Experimental Section

General

All moisture-sensitive and oxygen-sensitive reactions were carried out in flame-dried glassware under a nitrogen atmosphere. Dry DMSO and all other reagents were purchased at the highest commercial quality from Aldrich and Fisher Scientific USA) and used without further purification, unless otherwise stated. A CEM Discover microwave reactor was used to carry out all direct arylation reactions. HRESIMS spectra were obtained using an Agilent 6520 QTOF instrument. 1H NMR and 13C NMR spectra were recorded using Bruker DPX-500 spectrometer (operating at 500 MHz for 1H; 125 MHz, for 13C) using CDCl3 as solvent unless stated otherwise. Tetramethylsilane (δ 0.00 ppm) served as an internal standard in 1H NMR and CDCl3 (δ 77.0 ppm) in 13C NMR unless stated otherwise. Chemical shift (δ 0.00 ppm) values are reported in parts per million and coupling constants in Hertz (Hz). Splitting patterns are described as singlet (s), doublet (d), triplet (t), and multiplet (m). Reactions were monitored by TLC with Whatman Flexible TLC silica gel G/UV 254 precoated plates (0.25 mm). TLC plates were visualized by UV (254 nm) and by staining in an iodine chamber. Flash column chromatography was performed with silica gel 60 (EMD Chemicals, 230–400 mesh, 0.063 mm particle size).

Synthesis of compound 11 - procedure for acyl Pictet-Spengler reaction

At 5 °C, concentrated sulfuric acid (0.5 mL) was added dropwise to a solution of carbamate 9, (0.253 g, 1 mmol) and aldehyde 10 (0.229 g, 1 mmol) in acetic acid (5 mL). After stirring at room temperature for 2h, the reaction mixture was poured onto crushed ice-water and extracted with dichloromethane (10 mL). The organic layer was washed sequentially with water (10 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with gradient elution in 10% – 30% ethyl acetate/hexanes mixtures to yield 11 (0.360 g, 78%). Compounds 13a-13n, 15 and 18b were prepared in a similar manner. Compound 18 a was prepared via a Bischler-Napieralki reaction as described below.

Synthesis of compound 18a

graphic file with name nihms442499f7.jpg

Step 1

A solution of isonicotinic acid (0.147 g, 1.2 mmol) and 1,10-carbonyldiimidazole (0.194 g, 1.2 mmol) in anhydrous THF (10 mL) was stirred at 0 °C for 1.5 h and then, at room temperature for 1h. The mixture was cooled in an ice-bath and stirred for 1h. Then 2-(3-bromo-4,5-dimethoxyphenyl)ethanamine (0.260 g,1 mmol) was added and the solution was stirred at 0 °C for 4 h and left stirring overnight at room temperature. The reaction mixture was evaporated under reduced pressure and the residue was dissolved in ethyl acetate (20 mL) and washed with water (20 mL), saturated NaHCO3 solution (10 mL), then with water (10 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. This gave the crude product as a pale yellow gummy liquid (0.248 g, 68%).

graphic file with name nihms442499f8.jpg

Steps 2–4

To a mixture of the amide above (0.182 g, 0.5 mmol), P2O5 (1 g) in toluene (5 mL) was added POCl3 and refluxed for 3h. The solvent was evaporated under reduced pressure. The resulting solid was dissolved in water and carefully basified with solid NaHCO3. Once the liberation of CO2 had ceased, the aqueous layer was extracted with dichloromethane (10 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure and was used in the next step without further purification.

To a magnetically stirred ice-cooled solution of the crude imine from the previous reaction in a mixture of dry MeOH (10 mL), was added NaBH4 (0.174 g, 0.5 mmol) in three portions over 10 min. The reaction mixture was stirred at 0 °C for 2 h. The mixture was diluted with water and extracted with dichloromethane (5 mL). The combined organic layer dried over anhydrous Na2SO4 and concentrated in vacuo. The crude amine product was used in the next step without further purification.

To a solution of crude amine (0.174 g, 0.5 mmol) dissolved in dry dichloromethane (5 mL) was added DIPA (0.101 g, 1 mmol), DMAP (0.06 g, 0.05 mmol), and tert-butyl carbamate (0.087 g, 0.75 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 24 h, quenched with water (10 mL), and extracted with dichloromethane (10 mL). The organic layer was washed with water (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The resulting crude product, on column chromatography over silica gel using EtOAc/Hexanes (20:80) as eluant, furnished compound 18a (80 mg, 35.7%).

Compound 11

Yield 0.036 g (78%), white solid, Rf = 0.66 (silica gel, hexanes/EtOAc, 6:4), m.p. 117–119 °C. 1H NMR (CDCl3): δ= 1.23 (t, J=6.5 Hz, 3H), 2.75 (m, 1H), 2.96 (m, 1H), 3.37 (m, 1H), 3.75 (s, 3H), 3.86 (s, 3H), 4.16 (m, 3H), 5.92 (s, 1H), 5.93 (s, 1H), 6.36 (br. s, 1H), 6.49 (br. s, 1H), 6.51 (s, 1H), 6.65 (s, 1H), 7.05 (s, 1H). 13C NMR (CDCl3): δ= 14.6, 28.3, 39.4, 55.9 (×2), 57.2, 61.6, 101.8, 109.2, 110.4, 111.3 (×2), 112.8 (×2), 114.4, 126.6, 127.2, 147.4, 147.7, 148.0, 155.9. HRESIMS calculated for C21H23BrNO6 [M+H]+ 464.0703; found 464.0700.

Compound 13a

Yield 0.036 g (76%), colourless oil, Rf = 0.66 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.24 (t, J=6.5 Hz, 3H), 2.79 (m, 1H), 2.98 (m, 1H), 3.40 (m, 1H), 3.69 (s, 3H), 3.75 (s, 3H), 3.89 (s, 6H), 4.16 (q, J=6.5 Hz, 2H), 4.27 (m, 1H), 6.37 (br. s, 1H), 6.53 (br. s, 1H), 6.55 (s, 1H), 6.67 (s, 1H), 7.08 (s, 1H). 13C NMR (CDCl3): 14.6, 28.4, 39.6, 55.87, 55.90, 55.95, 56.1, 57.1, 61.6, 110.5, 111.2, 112.0, 114.3, 115.5, 126.6, 127.4, 135.4, 147.7, 147.9, 148.4, 148.7, 156.0. HRESIMS calculated for C22H27BrNO6 [M+H] + 480.0944; found 480.0938.

Compound 13b

Yield 0.030g (68%), white solid, Rf = 0.68 (silica gel, hexanes/EtOAc, 6:4), m.p. 126–128 °C. 1H NMR (CDCl3): δ= 1.23 (m, 3H), 2.82 (m, 1H), 2.97 (m, 1H), 3.42 (m, 1H), 3.76 (s, 3H), 3.90 (s, 3H), 4.16 (m, 3H), 6.41 (br. s, 1H), 6.55 (s, 1H), 6.67 (s, 1H), 6.77 (br. s, 1H), 6.86 (dd, J=8.0, 13.7 Hz, 1H), 7.59 (dd, J=5.5, 8.0 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.4, 39.6, 55.9 (×2), 57.3, 61.7, 110.3, 111.4 (×2), 116.0, 116.2, 126.5, 126.7, 134.2, 147.8, 148.2, 155.9, 161.1, 163.1. 19F NMR (CDCl3): δ= −114.5 (d, J= 375 Hz). HRESIMS calculated for C20H22BrFNO4 [M+H] + 438.0638; found 438.0636.

Compound 13c

Yield 0.029g (67%), colourless oil, Rf = 0.37 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.17 (m, 3H), 2.03, (br. s, 1H), 2.72 (m, 1H), 2.91 (m, 1H), 3.38 (m, 1H), 3.71 (s, 3H), 3.82 (s, 3H), 4.08 (m, 4H), 6.31 (s, 1H), 6.59 (m, 3H), 7.39 (d, J=8.0 Hz, 1H). 13C NMR (CDCl3): δ= 14.5, 28.2, 39.6, 55.8 (×2), 57.3, 61.9, 110.4, 111.2 (×2), 113.4 (×2), 116.5, 126.5, 127.0, 133.7, 144.9, 147.6, 147.9, 156.5. HRESIMS calculated for C20H23BrNO5 [M+H] + 436.0681; found 436.0679.

Compound 13d

Yield 0.032g (72%), colourless oil, Rf = 0.67 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.23 (m, 3H), 2.80 (m, 1H), 2.95 (m, 1H), 3.43 (m, 1H), 3.71 (s, 3H), 3.76 (s, 3H), 3.89 (s, 3H), 4.15 (m, 4H), 6.39 (br. s, 1H), 6.68 (m, 4H), 7.52 (d, J=8.5 Hz, 1H). 13C NMR (CDCl3): δ= 14.5, 28.3, 39.3, 55.4, 55.86, 55.90, 57.3, 61.6, 110.4, 111.25, 111.28 (×2), 113.7, 126.6, 127.1, 133.6, 147.8, 148.00, 148.02, 156.1, 159.2. HRESIMS calculated for C21H25BrNO5 [M+H]+ 450.0838; found 450.0834.

Compound 13e

Yield 0.031g (73.5%), colourless oil, Rf = 0.60 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.23 (m, 3H), 2.79 (m, 1H), 2.98 (m, 1H), 3.40 (m, 1H), 3.74 (s, 3H), 3.89 (s, 3H), 4.16 (m, 3H), 6.49 (br. s, 1H), 6.55 (s, 1H), 6.67 (s, 1H), 7.05 (br. s, 1H), 7.12 (m, 1H), 7.19 (m, 1H), 7.63 (d, J=7.9 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.2, 39.3, 55.9 (×2), 57.3, 61.6, 110.5, 111.3 (×2), 126.7, 127.2, 127.6, 128.8, 130.0, 133.1, 147.7, 148.03, 148.04, 155.9. HRESIMS calculated for C20H23BrNO4 [M+H]+ 420.0732; found 420.0728.

Compound 13f

Yield 0.028g (67%), white solid, Rf = 0.40 (silica gel, hexanes/EtOAc, 6:4), m.p. 129–131°C. 1H NMR (CDCl3): δ= 1.30 (m, 3H), 2.80 (m, 1H), 2.94 (m, 1H), 3.41 (m, 1H), 3.77 (s, 3H), 4.14 (m, 3H), 5.68 (s, 1H), 6.49 (br. s, 1H), 6.54 (s, 1H), 6.77 (m, 2H), 6.87 (m, 1H), 7.60 (dd, J=5.5, 8.5 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.0, 39.5, 55.9, 57.4, 61.7, 109.7, 114.5, 115.9, 116.1, 117.2, 117.9, 125.9, 127.4, 134.2, 144.9, 145.5, 155.9, 161.9. 19F NMR (CDCl3): δ= −113.5 (d, J= 360 Hz). HRESIMS calculated for C19H20BrFNO4 [M+H] + 420.0481; found 420.0477.

Compound 13g

Yield 0.030g (68%), white solid, Rf = 0.38 (silica gel, hexanes/EtOAc, 6:4), m.p. 105–107 °C. 1H NMR (CDCl3): δ= 1.22 (m, 3H), 2.77 (m, 1H), 2.93 (m, 1H), 3.42 (m, 1H), 3.71 (s, 3H), 3.77 (s, 3H), 4.15 (m, 3H), 5.56 (m, 1H), 6.39 (br. s, 1H), 6.56 (s, 1H), 6.61 (br. s, 1H), 6.69 (dd, J=3.5, 8.5 Hz, 1H), 6.74 (s, 1H), 7.51 (d, J=8.5 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.0, 39.4, 55.3, 55.9, 57.5, 61.6, 109.9, 113.8, 114.3 (×2), 115.7, 126.5 (×2), 127.4 (×2), 133.5, 143.8, 145.4, 155.9. HRESIMS calculated for C20H23BrNO5 [M+H] + 436.0681; found 436.0679.

Compound 13h

Yield 0.028g (70%), colourless oil, Rf = 0.39 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.20 (m, 3H), 2.71 (m, 1H), 2.90 (m, 1H), 3.34 (m, 1H), 3.71 (s, 3H), 4.14 (m, 3H), 5.70 (s, 1H), 6.43 (br. s, 1H), 6.50 (s, 1H), 6.72 (s, 1H), 7.02 (br. s, 1H), 7.09 (m, 1H), 7.17 (m, 1H), 7.60 (d, J=8.5 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.0, 38.4, 55.9, 57.4, 61.6, 109.9, 114.3 (×2), 124.2, 126.7, 127.5, 128.7, 129.8, 130.8, 133.1, 144.6, 145.4, 155.9. HRESIMS calculated for C19H21BrNO4 [M+H] + 408.0630; found 408.0630.

Compound 13i

Yield: 0.026g (62%), colourless oil, Rf = 0.40 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.21 (m, 3H), 2.82 (m, 1H), 2.95 (m, 1H), 3.42 (dd, J=10.5, 10.5 Hz, 1H), 3.89 (s, 3H), 4.14 (m, 3H), 5.57 (s, 1H), 6.36 (br. s, 1H), 6.58 (s, 1H), 6.66 (s, 1H), 6.76 (br. s, 1H), 6.84 (m, 1H), 7.56 (dd, J=5.5, 9.0 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.6, 39.8, 55.9, 57.2, 61.8, 110.5, 113.5, 115.9, 116.1, 126.3, 127.5, 134.3, 144.0, 146.14, 146.14, 156.3, 160.9, 163.2. 19F NMR (CDCl3): δ= −114.2 (d, J= 250 Hz). HRESIMS calculated for C19H20BrFNO4 [M+H] + 424.0553; found 424.0553.

Compound 13j

Yield: 0.032g (70%), white solid, Rf = 0.36 (silica gel, hexanes/EtOAc, 6:4), m.p. 161–163 °C. 1H NMR (CDCl3): δ= 1.24 (m, 3H), 2.77 (m, 1H), 2.94 (m, 1H), 3.39 (m, 1H), 3.89 (s, 3H), 4.15 (m, 3H), 5.48 (s, 1H), 5.94 (m, 2H), 6.33 (br. s, 1H), 6.55 (m, 2H), 6.64 (s, 1H), 7.05 (s, 1H). 13C NMR (CDCl3): δ= 14.2, 28.6, 39.7, 55.9, 57.1, 61.7, 101.8 (×2), 109.2, 110.7 (×2), 112.6, 113.6, 114.5, 126.0, 136.2, 144.3, 145.8, 147.4, 155.9. HRESIMS calculated for C20H21BrNO6 [M+H] + 452.0529; found 452.0527.

Compound 13k

Yield: 0.032g (73%), colourless oil, Rf = 0.38 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.18 (m, 3H), 2.75 (m, 1H), 2.92 (m, 1H), 3.40 (m, 1H), 3.66 (s, 3H), 3.85 (s, 3H), 4.11 (m, 3H), 5.70 (br. s, 1H), 6.33 (br. s, 1H), 6.65 (m, 4H), 7.46 (d, J=9.0 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 28.6, 39.8, 55.3, 55.9, 57.2, 61.7, 110.7, 111.3, 113.7, 114.9, 115.1, 121.4, 126.0, 127.9, 133.6, 144.3, 145.7, 156.0, 158.9. HRESIMS calculated for C20H23BrNO5 [M+H] + 436.0681; found 436.0676.

Compound 13l

Yield: 0.034g (73%), colourless oil, Rf = 0.35 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.20 (m, 3H), 2.25 (s, 1H), 2.76 (m, 1H), 2.96 (m, 1H), 3.39 (m, 1H), 3.67 (s, 3H), 3.86 (s, 6H), 4.14 (q, J=6.5 Hz, 2H), 4.28 (br. s, 1H), 6.29 (br. s, 1H), 6.55 (s, 1H), 6.56 (s, 1H), 6.63 (s, 1H), 7.03 (s, 1H). 13C NMR (CDCl3): δ= 14.6, 28.8, 39.9, 55.90, 55.95, 56.1, 57.0, 61.6, 110.5 (×2), 112.2, 113.6, 114.6, 115.4, 125.9, 128.1, 144.3, 145.6, 148.5, 148.6, 155.9. HRESIMS calculated for C21H25BrNO6 [M+H] + 466.0787; found 466.0785.

Compound 13m

Yield: 0.042g (82%), colourless oil, Rf = 0.62 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.13 (m, 3H), 2.62 (m, 1H), 3.08 (m, 1H), 3.34 (s, 3H), 3.51 (m, 1H), 3.62 (s, 3H), 3.81 (s, 3H), 3.83 (s, 3H), 3.86 (s, 3H), 4.07 (m, 2H), 4.38 (br. s, 1H), 6.14 (s, 1H), 6.33 (br. s, 1H), 6.75 (d, J=8.5 Hz, 1H), 7.34 (d, J=8.5 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 23.3, 39.9, 55.8, 55.9, 57.1, 59.6, 60.90, 60.94, 61.3, 105.7, 112.7, 116.8, 121.3, 127.6, 130.9, 136.8, 140.7, 148.4, 150.6, 151.6, 152.9, 156.1. HRESIMS calculated for C23H29BrNO7 [M+H] + 510.1049; found 510.1048

Compound 13n

Yield: 0.038g (80%), white solid, Rf = 0.67 (silica gel, hexanes/EtOAc, 6:4), m.p. 78–80 °C. 1H NMR (CDCl3): δ= 1.23 (m, 3H), 2.81 (m, 2H), 3.35 (m, 1H), 3.71 (s, 3H), 3.73 (s, 3H), 3.88 (s, 3H), 3.91 (s, 3H), 4.16 (m, 3H), 6.41 (br. s, 2H), 6.59 (br. s, 1H), 6.70 (dd, J=3.0, 8.5 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H). 13C NMR (CDCl3): 14.6, 22.4, 39.2, 55.4, 55.9, 57.4, 60.7, 60.8, 61.6, 106.5, 113.6, 114.8, 115.9, 116.2, 121.1, 130.6, 133.6, 140.9, 150.9, 152.0, 155.9, 158.9. HRESIMS calculated for C22H27BrNO6 [M+H] +: 480.0944; found 480.0939.

Compound 15

1:1 Mixture of rotamers (signals for one rotamer reported). Yield 0.037g (83%), colourless oil, Rf = 0.7 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.29 (m, 3H), 2.69 (m, 1H), 2.96 (m, 1H), 3.13 (m, 1H), 3.77 (s, 3H), 3.84 (s, 3H), 3.90 (s, 3H), 4.30 (m, 2H), 4.38 (m, 1H), 6.51 (s, 1H), 6.76 (m, 4H), 7.20 (m, 1H). 13C NMR (CDCl3): δ= 14.8, 28.2, 55.1, 56.1, 57.2, 57.4, 60.6, 61.7, 111.6, 112.3, 114.4, 119.5, 120.6, 127.5, 129.1, 132.5, 142.3, 145.0, 152.3, 155.0, 159.1. HRESIMS calculated for C21H25BrNO5 [M+H] +: 450.0838; found 450.0835.

Compound 18a

Mixture of rotamers (signals for one rotamer reported). Yield 0.080g (35.7%), colourless oil, Rf = 0.2 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.55 (m, 9H), 2.64 (m, 1H), 2.93 (m, 1H), 3.05 (m, 1H), 3.83 (m, 1H), 3.85 (s, 3H), 3.89 (s, 3H), 6.63 (s, 1H), 6.74 (m, 1H), 7.06 (m, 2H), 8.51 (m, 2H). 13C NMR (CDCl3): δ= 28.4, 37.3, 38.4, 55.8, 56.1, 60.6, 76.8, 77.1, 80.5, 112.0, 119.0, 119.5, 122.7, 126.5, 126.6, 132.8, 145.3, 149.8, 150.1, 152.8, 154.8. HRESIMS calculated for C21H26BrN2O4 [M+H]+ 449.0998; found 449.0996.

Compound 18b

Yield 0.034g (82%), colourless oil, Rf = 0.2 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.18 (m, 3H), 2.93 (m, 2H), 3.46 (m, 1H), 3.73 (s, 3H), 3.86 (s, 3H), 4.12 (m, 3H), 6.36 (br. s, 1H), 6.55 (d, J=4.5 Hz, 1H), 6.66 (d, J=4.5 Hz, 1H), 7.03 (br. s, 1H), 8.37 (s, 1H), 8.75 (s, 1H). 13C NMR (CDCl3): δ= 14.5, 28.3, 40.0, 55.9, 56.7, 61.9, 109.9, 111.44, 122.3, 125.4, 126.7, 148.2, 149.1, 153.4, 156.5. HRESIMS calculated for C19H22BrN2O4 [M+H] + 421.0685; found 421.0687.

Synthesis of compound 12 - procedure for microwave-assisted direct arylation reaction

In a microwave reaction vial, dihydroisoquinoline 11 (0.046 g, 0.1 mmol), Pd(OAc)2 (0.0044g, 0.02 mmol), ligand C (0.0099 g, 0.04 mmol) and K2CO3 (0.0276 g, 0.2 mmol) were added and dissolved in Ar-purged anhydrous, degassed DMSO (0.5 mL). The mixture was irradiated in a CEM Discover microwave reactor for 5 min at 135 °C with the power level at 300W. After cooling to room temperature, the reaction mixture was quenched with water (10 mL) and extracted with dichloromethane (5 mL). The solvents were evaporated under reduced pressure and the crude product was purified by flash column chromatography eluted with 10 – 20% EtOAc/hexanes. This furnished the cyclized product 12. Compounds 14a-14n, 16a, 16b and 19 were obtained in a similar manner.

Compound 12

Yield 0.034g (91%), colourless oil, Rf = 0.67 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.42 (t, J=7.0 Hz, 3H), 2.66 (m, 2H), 2.88 (m, 1H), 3.93 (s, 3H), 3.98 (s, 3H), 4.38 (m, 2H), 4.51 (m, 1H), 5.46 (s, 1H), 6.02 (d, J=1.2 Hz, 1H), 6.03 (d, J=1.2 Hz, 1H), 6.61 (s, 1H), 7.51 (s, 2H). 13C NMR (CDCl3): δ= 14.9, 29.8, 44.8, 56.5, 58.5, 60.7, 62.0, 101.3, 104.3, 108.0, 108.6 (×2), 131.3, 132.8, 133.7, 142.1, 142.7, 146.9, 147.6, 153.3, 158.1. HRESIMS calculated for C21H22NO6 [M+H]+ 384.1369; found 384.1365.

Compound 14a

Yield 0.0356g (89%), colourless oil, Rf = 0.67 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (t, J= 6.5 Hz, 3H), 2.67 (m, 2H), 2.90 (m, 1H), 3.90 (s, 3H), 3.96 (s, 3H), 4.00 (s, 6H), 4.38 (m, 2H), 4.52 (m, 1H), 5.50 (s, 1H), 6.62 (s, 1H), 7.58 (br. s, 2H). 13C NMR (CDCl3): δ= 14.9, 29.9, 44.8, 56.1, 56.2, 56.4, 58.7, 60.6, 61.9, 106.6, 108.8 (×2), 110.3, 131.4, 131.6, 133.7, 140.7, 142.7, 148.3, 149.2, 153.3, 157.9. HRESIMS calculated for C22H26NO6 [M+H]+ 400.1755; found 400.1753.

Compound 14b

Yield 0.031g (86%), colourless oil, Rf = 0.7 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ=1.43 (t, J=6.7 Hz, 3H), 2.69 (m, 2H), 2.89 (m, 1H), 3.94 (s, 3H), 3.99 (s, 3H), 4.39 (t, J=6.7 Hz, 2H), 4.52 (m, 1H), 5.53 (s, 1H), 6.67 (s, 1H), 7.09 (m, 1H), 7.71 (br. s, 1H), 7.96 (dd, J=5.5, 8.4 Hz, 1H). 13C NMR (CDCl3): δ= 14.7, 29.8, 44.6, 56.4, 58.69, 58.71, 60.6, 62.1, 109.4, 114.9, 115.1, 124.4, 131.5, 133.5, 134.9, 143.2, 150.0, 153.4, 157.9, 162.0. 19F NMR (CDCl3): δ= −114.1 (d, J= 375 Hz). HRESIMS calculated for C20H21FNO4 [M+H] + 358.1449; found 358.1450.

Compound 14c

Yield 0.029g (81%), colourless oil, Rf = 0.38 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ=1.41 (t, J= 7.0 Hz, 3H), 1.70 (br. s. 1H), 2.67 (m, 2H), 2.89 (m, 1H), 3.93 (s, 3H), 3.98 (s, 3H), 4.37 (q, J=7.0 Hz, 2H), 4.49 (m, 1H), 5.56 (s, 1H), 6.61 (s, 1H), 6.90 (dd, J=2.0, 8.0 Hz, 1H), 7.65 (br. s, 1H), 7.86 (d, J=8.0 Hz, 1H). 13C NMR (CDCl3): δ=14.7, 29.9, 44.7, 56.4, 58.8, 60.6, 62.2, 108.5, 114.4, 115.1, 124.51, 131.2, 131.3, 131.6, 133.1, 142.8, 149.7, 153.4, 155.7, 158.5. HRESIMS calculated for C20H22NO5 [M+H]+ 356.1492; found 356.1491.

Compound 14d

Yield 0.031g (83%), colourless oil, Rf = 0.66 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.41 (t, J= 7.2 Hz, 3H), 2.64 (m, 2H), 2.86 (m, 1H), 3.85 (s, 3H), 3.90 (s, 3H), 3.96 (s, 3H), 4.36 (q, J=7.2 Hz, 2H), 4.52 (m, 1H), 5.53 (s, 1H), 6.59 (s, 1H), 6.92 (dd, J=2.4, 8.4 Hz, 1H), 7.53 (br. s, 1H), 7.89 (d, J=8.4 Hz, 1H). 13C NMR (CDCl3): δ= 14.8, 29.9, 44.7, 55.5, 56.4, 58.9, 60.6, 61.9, 108.6, 112.4, 113.9 (×2), 124.2, 131.4, 131.6, 133.3, 142.8, 149.7, 153.3, 157.9, 159.1. HRESIMS calculated for C21H24NO5 [M+H]+ 370.1649; found 370.1652.

Compound 14e

Yield 0.028g (82%), colourless oil, Rf = 0.61 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (t, J=7.1 Hz, 3H), 2.68 (m, 2H), 2.89 (m, 1H), 3.93 (s, 3H), 4.01 (s, 3H), 4.40 (q, J=7.1 Hz, 2H), 4.55 (m, 1H), 5.60 (s, 1H), 6.69 (s, 1H), 7.30 (dd, J=7.6, 7.6 Hz, 1H), 7.41 (m, 1H), 7.97 (s, 1H), 8.05 (d, J=7.6 Hz, 1H). 13C NMR (CDCl3): δ= 14.8, 29.9, 44.7, 56.5, 58.9, 60.6, 61.9, 109.8, 123.7, 126.4, 126.9, 128.2 (×2), 131.5, 133.8, 138.9, 143.7, 147.7, 153.3, 157.9. HRESIMS calculated for C20H22NO4 [M+H]+ 340.1543; found 340.1549.

Compound 14f

Yield 0.026g (77%), colourless oil, Rf = 0.41 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (t, J=7.0 Hz, 3H), 2.67 (m, 2H), 2.89 (m, 1H), 4.00 (s, 3H), 4.39 (m, 2H), 4.52 (m, 1H), 5.55 (s, 1H), 5.78 (s, 1H), 6.74 (s, 1H), 7.12 (m, 1H), 7.79 (m, 2H). 13C NMR (CDCl3): δ= 14.8, 29.7, 44.6, 58.8, 61.5, 62.1, 112.2, 114.4, 114.9, 115.2, 123.8, 132.7, 133.5, 134.2, 141.0, 149.7, 150.7, 157.8, 162.1. 19F NMR (CDCl3): δ= −114.4 (d, J= 360 Hz). HRESIMS calculated for C19H19FNO4 [M+H]+ 344.1220; found 344.1217.

Compound 14g

Yield 0.029 (82%), colourless oil, Rf = 0.39 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (t, J=7.0 Hz, 3H), 2.66 (m, 2H), 2.87 (m, 1H), 3.89 (s, 3H), 4.00 (s, 3H), 4.38 (q, J=7.0 Hz, 2H), 4.52 (m, 1H), 5.56 (s, 1H), 5.78 (br. s, 1H), 6.68 (s, 1H), 6.97 (dd, J=1.5, 8.5 Hz, 1H), 7.60 (br. s, 1H), 7.75 (d, J=8.5 Hz, 2H). 13C NMR (CDCl3): δ= 14.8, 29.8, 44.7, 55.6, 59.0, 61.4, 61.9, 111.3, 112.7, 113.9, 123.7, 130.9, 132.5, 133.2, 140.5, 149.4, 150.0, 158.0, 159.2. HRESIMS calculated for C20H22NO5 [M+H]+ 356.1492; found 356.1497.

Compound 14h

Yield 0.026g (81%), colourless oil, Rf = 0.39 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (t, J=7.0 Hz, 3H), 2.67 (m, 2H), 2.89 (m, 1H), 4.02 (s, 3H), 4.39 (t, J=7.0 Hz, 2H), 4.54 (m, 1H), 5.59 (s, 1H), 5.79 (s, 1H), 6.75 (s, 1H), 7.31 (m, 2H), 7.43 (dd, J=7.5, 7.5 Hz, 1H), 7.87 (d, J=7.5 Hz, 1H), 7.98 (br. s, 1H). 13C NMR (CDCl3): δ= 14.8, 29.8, 44.7, 59.1, 61.6, 61.9, 112.6, 123.2, 126.5, 127.1, 128.4, 130.5, 132.7, 133.8, 138.3, 141.2, 148.1, 149.3, 157.9. HRESIMS calculated for C19H20NO4 [M+H]+ 326.1314; found 326.1313.

Compound 14i

Yield 0.026g (76%), colourless oil, Rf = 0.41 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ=1.43 (t, J=7.1 Hz, 3H), 2.65 (m, 2H), 2.86 (m, 1H), 3.95 (s, 3H), 4.40 (q, J=7.1 Hz, 2H), 4.53 (m, 1H), 5.56 (s, 1H), 5.99 (s, 1H), 6.62 (s, 1H), 7.08 (m, 1H), 7.67 (br. s, 1H), 7.96 (dd, J=5.4, 8.2 Hz, 1H). 13C NMR (CDCl3): δ= 14.7, 29.6, 44.9, 56.7, 58.9, 61.9, 107.5, 114.7, 114.9, 124.5, 127.1, 133.8, 135.1, 139.9, 147.2, 149.5, 157.9, 160.8, 162.8. HRESIMS calculated for C19H19FNO4 [M+H]+ 344.1220; found 344.1227.

Compound 14j

Yield 0.030g (81%), colourless oil, Rf = 0.38 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.42 (m, 3H), 2.64 (m, 2H), 2.85 (m, 1H), 3.94 (s, 3H), 4.38 (m, 2H), 4.52 (m, 1H), 5.48 (s, 1H), 5.92 (s, 1H), 6.00 (s, 1H), 6.02 (s, 1H), 6.57 (s, 1H), 7.53 (br. s, 2H). 13C NMR (CDCl3): δ= 14.7, 29.6, 44.8, 56.6, 58.7 (×2), 61.9, 101.2 (×2), 104.5, 106.8, 126.9, 133.1, 134.1, 139.3, 141.5, 146.5, 147.1, 147.5, 157.9. HRESIMS calculated for C20H20NO6 [M+H]+ 370.1285; found 370.1289.

Compound 14k

Yield 0.027g (77%), colourless oil, Rf = 0.39 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.44 (t, J=7.0 Hz, 3H), 2.65 (m, 2H), 2.85 (m, 1H), 3.87 (s, 3H), 3.94 (s, 3H), 4.40 (q, J=7.0 Hz, 2H), 4.53 (m, 1H), 5.58 (s, 1H), 5.94 (s, 1H), 6.57 (s, 1H),6.95 (dd, J=2.0, 8.3 Hz, 1H), 7.55 (br. s, 1H), 7.92 (d, J=8.3 Hz, 1H). 13C NMR (CDCl3): δ=14.8, 29.7, 44.8, 55.5, 56.5, 59.0, 61.8, 106.8, 112.4, 113.6, 124.2, 126.9 (×2), 131.9, 133.6, 139.4, 147.1, 149.1, 157.9, 158.7. HRESIMS calculated for C20H22NO5 [M+H]+ 356.1492; found 356.1491.

Compound 14l

Yield 0.030g (79%), colourless oil, Rf = 0.36 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (m, 3H), 2.65 (m, 2H), 2.88 (m, 1H), 3.95 (s, 3H), 3.96 (s, 3H), 4.00 (s, 3H), 4.41 (m, 2H), 4.52 (m, 1H), 5.51 (s, 1H), 5.92 (s, 1H), 6.57 (s, 1H), 7.59 (br. s, 2H). 13C NMR (CDCl3): δ= 14.9, 29.8, 44.9, 56.07, 56.14, 56.7, 58.9, 61.9, 106.7(×2), 110.4, 126.9, 131.9, 134.1, 139.3, 139.9, 147.2, 147.9, 149.1, 158.0. HRESIMS calculated for C21H24NO6 [M+H]+ 386.1598; found 386.1597.

Compound 14m

Yield 0.040g (93%), colourless oil, Rf = 0.61 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.10 (m, 3H), 2.65 (m, 1H), 2.90 (m, 1H), 3.79 (m, 2H), 3.89 (s, 6H), 3.91 (s, 3H), 3.93 (s, 3H), 3.98 (s, 3H), 4.06 (m, 2H), 5.40 (s, 1H), 6.92 (d, J=8.0 Hz, 1H), 7.56 (d, J=8.0 Hz,1H). 13C NMR (CDCl3): δ= 14.3, 22.7, 45.5, 56.2, 60.5, 60.7, 60.8, 61.1, 61.2, 61.4, 76.8, 112.6, 118.1, 122.5, 126.2, 132.6, 137.7, 146.3, 146.6, 147.3, 150.3, 151.7, 157.1. HRESIMS calculated for C23H28NO7 [M+H]+ 430.1860; found 430.1861.

Compound 14n

Yield 0.036g (91%), colourless oil, Rf = 0.62 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.43 (t, J=7.0 Hz, 3H), 2.63 (m, 2H), 2.99 (m, 1H), 3.87 (s, 3H), 3.92 (s, 3H), 3.98 (s, 3H), 4.03 (s, 3H), 4.40 (q, J=7.0 Hz, 2H), 4.55 (m, 1H), 5.53 (s, 1H), 6.93 (dd, J=2.5, 8.5 Hz, 1H), 7.53 (br. s, 1H), 7.83 (d, J=8.5 Hz, 1H). 13C NMR (CDCl3): δ= 14.8, 24.6, 44.3, 55.6, 59.2, 60.9, 61.3, 61.8, 62.0, 112.2, 113.9, 123.5, 124.8, 126.8, 131.8, 136.6, 146.0, 147.5, 149.0, 149.2, 157.8, 158.6. HRESIMS calculated for C22H26NO6 [M+H]+ 400.1755; found 400.1757.

Compound 16a

Yield 0.019g (46%), colourless oil, Rf = 0.46 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.15 (t, J= 7.5 Hz, 3H), 3.20 (m, 2H), 3.43 (m, 2H), 3.84 (s, 3H), 3.87 (s, 3H), 3.95 (s, 3H), 3.98 (s, 3H), 4.05 (m, 2H), 5.03 (br. s, 1H), 6.95 (dd, J=2.5, 8.0 Hz, 1H), 7.13 (d, J=2.5 Hz, 1H), 7.63 (d, J=8.0 Hz, 1H). 13C NMR (CDCl3): δ= 14.6, 24.5, 29.7, 41.6, 55.6, 60.4, 60.5, 60.8, 61.2, 109.1 (×2), 120.0, 124.1(×2), 127.3, 131.3, 134.7, 136.4, 147.3, 152.2, 156.7, 160.1. HRESIMS calculated for C22H26NO7 [M+H]+ 416.1631; found 416.1632.

Compound 16b

Yield 0.019g (53%), colourless oil, Rf = 0.46 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.21 (m, 3H), 3.22 (m, 2H), 3.50 (m, 2H), 3.97 (s, 6H), 4.11 (q, J=7.1 Hz, 2H), 6.56 (s, 1H), 7.31 (m, 2H), 7.50 (m, 1H), 7.62 (d, J=7.4 Hz, 1H), 7.87 (d, J=7.4 Hz, 1H). 13C NMR (CDCl3): δ= 14.67, 31.6, 41.7, 56.2, 60.4, 60.7, 113.4, 123.6, 123.9, 124.6, 128.77, 134.5, 135.4, 137.9, 141.9, 143.7, 156.8, 158.7. HRESIMS calculated for C20H22NO5 [M+H]+ 356.1492; found 356.1491.

Compound 19

Yield 0.035g (91%), colourless oil, Rf = 0.1 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 1.41 (s, 9H), 3.23 (m, 2H), 3.44 (m, 2H), 3.98 (s, 3H), 4.01 (s, 3H), 4.77 (br. s, 1H), 6.64 (s, 1H), 7.48 (d, J=4.5 Hz, 1H), 8.70 (d, J=4.5 Hz, 1H), 9.16 (s, 1H). 13C NMR (CDCl3): δ= 28.2, 32.1, 41.1, 56.0, 60.5, 114.5, 116.9, 124.1, 135.6, 139.6, 141.5, 143.9, 144.9, 151.5, 156.2, 159.1. HRESIMS calculated for C21H25N2O5 [M+H]+ 385.1758; found 385.1758.

Synthesis of compound 17 - procedure for deprotection and oxidation to azafluoranthenes

To a solution of azafluoranthene 12 (0.038 g, 0.1 mmol) in dry DMSO (1 mL) was added DBU (0.152 g, 1 mmol) under N2 and the reaction mixture was purged with oxygen (balloon). The reaction mixture was stirred at 40 °C for 8h. Water (5 mL) was added to the reaction mixture and extracted with dichloromethane (5 mL). The organic layer was washed sequentially with water (5 mL) and brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel in 30% ethyl acetate/hexanes to yield 17 (79%). Similar procedures were used to synthesize compounds 1 (76%) and 3 (77%).

Compound 17

Yield 0.030g (79%), pale yellow oil, Rf = 0.3 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 4.05 (s, 3H), 4.11 (s, 3H), 6.10 (s, 2H), 6.96 (s, 1H), 7.37 (d, J=6.0 Hz, 1H), 7.53 (s, 1H), 7.57 (s, 1H), 8.55 (d, J=6.0 Hz, 1H). 13C NMR (CDCl3): δ= 56.3, 61.3, 101.7, 103.2, 104.1, 106.0, 116.5, 123.1, 126.1, 130.1, 133.0, 133.9, 145.4, 147. 0, 148.0, 149.1, 158.7, 159.0. HRESIMS calculated for C18H14NO4 [M+H]+ 308.0917; found 308.0918.

Compound 1

Yield 0.025g (76%), colourless oil, Rf = 0.32 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 3.96 (s, 3H), 4.07 (s, 3H), 4.13 (s, 3H), 4.15 (s, 3H), 6.99 (dd, J =2.5, 8.5 Hz, 1H), 7.66 (d, J=6.0 Hz, 1H), 7.70 (d, J=2.5 Hz, 1H), 7.85 (d, J=8.5 Hz, 1H), 8.62 (d, J=6.0 Hz, 1H). 13C NMR (CDCl3): δ= 55.7, 61.45, 61.49, 62.1, 107.3, 113.8, 116.0, 122.2, 124.1, 124.6, 126.3, 131.1, 140.3, 144.6, 148.4, 149.9, 150.6, 159.0, 159.8. HRESIMS calculated for C19H18NO4 [M+H]+ 324.1230; for 324.1231.

Compound 3

Yield 0.021g (77%), colourless oil, Rf = 0.34 (silica gel, hexanes/EtOAc, 6:4). 1H NMR (CDCl3): δ= 4.05 (s, 3H), 4.12 (s, 3H), 7.02 (s, 1H), 7.45 (m, 3H), 8.04 (m, 1H), 8.10 (m, 1H), 8.60 (dd, J=5.0, 5.0 Hz, 1H). 13C NMR (CDCl3): δ=56.4, 61.4, 104.7, 117.1, 121.9, 123.3, 124.8, 126.6, 128.4, 129.8, 131.1, 138.2, 139.2, 145.7, 147.8, 159.1. HRESIMS calculated for C17H14NO2 [M+H]+ 264.1019; found 264.1020.

Synthesis of Compound 20

Compound 19 (44mg, 0.1 mmol), which was synthesized following the general procedure for direct arylation, was dissolved in DCM: TFA (1:1, 1 mL) and stirred at room temperature for 3 hours. Solvents were evaporated under reduced pressure and the residue was re dissolved in DCM (5 mL). The DCM layer was washed with 5% NaHCO3 solution (5 mL), water (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel eluted in neat ethyl acetate to give 20 (31 mg, 90%).

Compound 20

Yield 0.030g (90%), colourless oil, Rf = 0.51 (silica gel, 100% EtOAc, 6:4). 1H NMR (CDCl3): δ= 2.83 (t, J=8.5 Hz, 2H), 3.93 (s, 3H), 3.99 (s, 3H), 4.27 (t, J=8.5 Hz, 2H), 6.62 (s, 1H), 7.69 (d, J=5.0 Hz, 1H), 8.64 (d, J= 5.0 Hz, 1H), 9.11 (s, 1H). 13C NMR (CDCl3): δ= 22.6, 50.8, 56.4, 60.8, 110.8, 116.6, 121.2, 128.4, 129.9, 136.3, 143.5, 144.33, 145.0, 149.7, 157.9, 165.0. HRESIMS calculated for C16H15N2O2 [M+H]+ 267.1128; found 267.1130.

Synthesis of Compound 21

Compound 20 (0.017 g, 0.05 mmol) was dissolved in DCM (0.5 mL) and DBU (0.015 g, 0.1 mmol) was added to the reaction mixture at rt. The resulting dark brown solution was stirred at rt under open air for 4h. Water (5 mL) was added to the reaction mixture and extracted with DCM (5 mL). The DCM layer was washed with water, brine, dried on Na2SO4, filtered and concentrated in vacuo. The residue was purified by chromatography on silica gel in 50% ethyl acetate/hexanes to afford 21 (0.014g, 83%).

Compound 21

Yield 0.014g (83%), pale yellow oil, Rf = 0.52 (silica gel, 100% EtOAc). 1H NMR (CDCl3): δ= 4.09 (s, 3H), 4.18 (s, 3H), 7.10 (s, 1H), 7.57 (d, J=5.5 Hz, 1H), 8.10 (dd, J= 1.0, 5.0 Hz, 1H), 8.71 (d, J=5.5 Hz, 1H), 8.73 (d, J=5.0 Hz, 1H), 9.28 (s, 1H). 13C NMR (CDCl3): δ= 56.6, 61.7, 105.3, 116.4, 116.6, 118.8, 123.8, 124.2, 131.2, 132.8, 145.3, 146.2, 148.5, 149.8, 156.6, 159.3. HRESIMS calculated for C16H13N2O2 [M+H]+ 265.0977; found 265.0978.

Supplementary Material

Supporting Information

Figure 1.

Figure 1

Structures of the azafluoranthene alkaloids rufescine (1), imeluteine (2) and triclisine (3) and the aporphine alkaloid nantenine (4)

Acknowledgments

This publication was made possible by Grant Number 1SC1GM092282 from the National Institute of General Medical Sciences (NIGMS) a component of the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or its divisions. (“Acknowledgment” on the Styles toolbar).

References

  • 1.a) Cava MP, Buck KT, Noguchi I, Srinivasan M, Rao MG, DaRocha AI. Tetrahedron. 1975;31:1667–1669. [Google Scholar]; b) Cava MP, Buck KT, DaRocha AI. J. Amer. Chem. Soc. 1972;94:5931. doi: 10.1021/ja00771a087. [DOI] [PubMed] [Google Scholar]
  • 2.Huls R, Gaspers J, Warin R. Bull. Soc. R. Sci. Liege. 1976;45:40–45. [Google Scholar]
  • 3.Menachery MD, Cava MP. J. Nat. Prod. 1981;44:320–323. [Google Scholar]
  • 4.Tang L-J, Guan H-Y, Zhang Y-H, He L, Yang X-S, Hao X-J. Zhong Yao Cai. 2010;33:1881–1883. [PubMed] [Google Scholar]
  • 5.Morita H, Matsumoto K, Takeya K, Itokawa H. Chem. Pharm. Bull. 1993;41:1307–1308. doi: 10.1248/cpb.41.1478. [DOI] [PubMed] [Google Scholar]
  • 6.Yan M-H, Cheng P, Jiang Z-Y, Ma Y-B, Zhang X-M, Zhang F-X, Yang L-M, Zheng Y-T, Chen J-J. J. Nat. Prod. 2008;71:760–763. doi: 10.1021/np070479+. [DOI] [PubMed] [Google Scholar]
  • 7.Shoji N, Umeyama A, Takemoto T, Ohizumi Y. J. Pharm. Sci. 1984;73:568–570. doi: 10.1002/jps.2600730435. [DOI] [PubMed] [Google Scholar]
  • 8.a) Liu Y, Liu J, Di D. Zhongcaoyao. 2012;43:806–814. [Google Scholar]; b) Stevigny C, Bailly C, Quetin-Leclercq J. Curr. Med. Chem.: Anti-Cancer Agents. 2005;5:173–182. doi: 10.2174/1568011053174864. [DOI] [PubMed] [Google Scholar]
  • 9.a) Herman EH, Chadwick DP. Pharmacology. 1973;10:178–187. doi: 10.1159/000136438. [DOI] [PubMed] [Google Scholar]; b) Orallo F. Planta Med. 2004;70:117–126. doi: 10.1055/s-2004-815487. [DOI] [PubMed] [Google Scholar]; c) Fernandez AA, Orallo F, Loza I, Cadavid M. Ars. Pharm. 1992;33:572–577. [Google Scholar]
  • 10.a) Zetler G. Arch. Int. Pharmacodyn. Ther. 1988;296:255–281. [PubMed] [Google Scholar]; b) Ribeiro RA, Leite JR. Phytomedicine. 2003;10:563–568. doi: 10.1078/094471103322331557. [DOI] [PubMed] [Google Scholar]; c) Anlezark GM, R. Blackwood DH, Meldrum BS, Ram VJ, Neumeyer JL. Psychopharmacology (Berlin) 1983;81:135–139. doi: 10.1007/BF00429007. [DOI] [PubMed] [Google Scholar]; d) Neumeyer JL, Law SJ, Meldrum B, Anlezark G. Adv. Biosci. 1982;37:291–296. [Google Scholar]
  • 11.a) Cassels BK, Asencio M. Nat. Prod. Commun. 2008;3:643–653. [PubMed] [Google Scholar]; b) Zhang A, Zhang Y, Branfman AR, Baldessarini RJ, Neumeyer JL. J. Med. Chem. 2007;50:171–181. doi: 10.1021/jm060959i. [DOI] [PubMed] [Google Scholar]
  • 12.Yang Z-d, Zhang X, Du J, Ma Z-j, Guo F, Li S, Yao X-j. Nat. Prod. Res. 2012;26:387–392. doi: 10.1080/14786419.2010.487188. [DOI] [PubMed] [Google Scholar]
  • 13.a) Chaudhary S, Ponnala S, Legendre O, Gonzales JA, Navarro HA, Harding WW. Bioorg. Med. Chem. 2011;19:5861–5868. doi: 10.1016/j.bmc.2011.08.019. [DOI] [PMC free article] [PubMed] [Google Scholar]; b Pecic S, Makkar P, Chaudhary S, Reddy BV, Navarro HA, Harding WW. Bioorg. Med. Chem. 2010;18:5562–5575. doi: 10.1016/j.bmc.2010.06.043. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Chaudhary S, Pecic S, Legendre O, Harding WW. Tetrahedron Lett. 2009;50:2437–2439. doi: 10.1016/j.tetlet.2009.03.029. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Legendre O, Pecic S, Chaudhary S, Zimmerman SM, Fantegrossi WE, Harding WW. Bioorg. Med. Chem. Lett. 2010;20:628–631. doi: 10.1016/j.bmcl.2009.11.053. [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Chaudhary S, Pecic S, Legendre O, Navarro HA, Harding WW. Bioorg. Med. Chem. Lett. 2009;19:2530–2532. doi: 10.1016/j.bmcl.2009.03.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ponnala S, Chaudhary S, Gonzalez-Sarrias A, Seeram NP, Harding WW. Bioorg. Med. Chem. Lett. 2011;21:4462–4464. doi: 10.1016/j.bmcl.2011.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Pecic S, McAnuff MA, Harding WW. J. Enzyme Inhib. Med. Chem. 2011;26:46–55. doi: 10.3109/14756361003671078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Swaffar DS, Holley CJ, Fitch RW, Elkin KR, Zhang C, Sturgill JP, Menachery MD. Planta Med. 2012;78:230–232. doi: 10.1055/s-0031-1280383. [DOI] [PubMed] [Google Scholar]
  • 17.Khan SI, Nimrod AC, Mehrpooya M, Nitiss JL, Walker LA, Clark AM. Antimicrob. Agents Chemother. 2002;46:1785–1792. doi: 10.1128/AAC.46.6.1785-1792.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.a) Gasiorski P, Danel KS, Matusiewicz M, Uchacz T, Vlokh R, Kityk AV. J. Fluoresc. 2011;21:443–451. doi: 10.1007/s10895-010-0722-1. [DOI] [PubMed] [Google Scholar]; b) Gasiorski P, Danel KS, Matusiewicz M, Uchacz T, Kuznik W, Kityk AV. J. Fluoresc. 2012;22:81–91. doi: 10.1007/s10895-011-0932-1. [DOI] [PubMed] [Google Scholar]; c) Danel KS, Gasiorski P, Matusiewicz M, Calus S, Uchacz T, Kityk AV. Spectrochim. Acta, Part A. 2010;77A:16–23. doi: 10.1016/j.saa.2010.04.006. [DOI] [PubMed] [Google Scholar]; d) Calus S, Danel KS, Uchacz T, Kityk AV. Mater. Chem. Phys. 2010;121:477–483. [Google Scholar]
  • 19.a) Menachery MD, Muthler CD. J. Nat. Prod. 1987;50:726–729. [Google Scholar]; b) Menachery MD, Buck KT. Heterocycles. 1985;23:2677–2679. [Google Scholar]; c) Cava MP, Buck KT, DaRocha AI. J. Am. Chem. Soc. 1972;94:5931. doi: 10.1021/ja00771a087. [DOI] [PubMed] [Google Scholar]; d) Banwell MG, Hamel E, Ireland NK, Mackay MF, Serelis AK. J. Chem. Soc., Perkin Trans. 1. 1993:1905–1911. [Google Scholar]; e) Menachery MD, Cava MP, Buck KT, Prinz WJ. Heterocycles. 1982;19:2255–2257. [Google Scholar]
  • 20.Ramana MMV, Sharma RH, Parihar JA. Tetrahedron Lett. 2005;46:4385–4386. [Google Scholar]
  • 21.Molina P, Garcia-Zafra S, Fresneda PM. Synlett. 1995:43–45. [Google Scholar]
  • 22.a) Fu JM, Zhao BP, Sharp MJ, Snieckus V. Can. J. Chem. 1994;72:227–236. [Google Scholar]; b) Zhao B, Snieckus V. Tetrahedron Lett. 1991;32:5277–5278. [Google Scholar]
  • 23.Boger DL, Mullican MD. J. Org. Chem. 1984;49:4033–4044. [Google Scholar]
  • 24.Hickey DMB, MacKenzie AR, Moody CJ, Rees CW. J. Chem. Soc., Perkin Trans. 1. 1987:921–926. [Google Scholar]
  • 25.Silveira CC, Larghi EL, Mendes SR, J. Bracca AB, Rinaldi F, Kaufman TS. Eur. J. Org. Chem. 2009:4637–4645. S4637/4631-S4637/4627. [Google Scholar]
  • 26.Chaudhary S, Harding WW. Tetrahedron. 2011;67:569–575. doi: 10.1016/j.tet.2010.11.059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.a) Lafrance M, Blaquiere N, Fagnou K. Eur. J. Org. Chem. 2007:811–825. [Google Scholar]; b) Lafrance M, Blaquiere N, Fagnou K. Chem. Commun. (Cambridge, U.K.) 2004:2874–2875. doi: 10.1039/b410394g. [DOI] [PubMed] [Google Scholar]
  • 28.Awuah E, Capretta A. J. Org. Chem. 2010;75:5627–5634. doi: 10.1021/jo100980p. [DOI] [PubMed] [Google Scholar]
  • 29.Lafrance M, Blaquiere N, Fagnou K. Chem. Commun. 2004:2874–2875. doi: 10.1039/b410394g. [DOI] [PubMed] [Google Scholar]
  • 30.a) Garcia-Cuadrado D, de MP, C. Braga AA, Maseras F, Echavarren AM. J. Am. Chem. Soc. 2007;129:6880–6886. doi: 10.1021/ja071034a. [DOI] [PubMed] [Google Scholar]; b) Gorelsky SI, Lapointe D, Fagnou K. J. Am. Chem. Soc. 2008;130:10848–10849. doi: 10.1021/ja802533u. [DOI] [PubMed] [Google Scholar]
  • 31.Dong J, Shi X-X, Yan J-J, Xing J, Zhang Q, Xiao S. Eur. J. Org. Chem. 2010:6987–6992. S6987/6981-S6987/6977. [Google Scholar]
  • 32.Castro-Castillo V, Rebolledo-Fuentes M, Cassels BK. J. Chil. Chem. Soc. 2009;54:417–423. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

RESOURCES